Effects of alendronate sodium on bone mineral density in maintenance hemodialysis patients with osteoporosis
- VernacularTitle:阿仑膦酸钠对维持性血液透析骨质疏松患者骨密度的影响
- Author:
Shu RONG
;
Chaoyang YE
;
Xuezhi ZHAO
;
Jing CHEN
;
Bin ZHANG
;
Changlin MEI
- Publication Type:Journal Article
- Keywords:
Alendronate;
Bone density;
Renal dialysis;
Osteoporosis
- From:
Chinese Journal of Nephrology
2008;24(11):779-782
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of alendronate sodium on bone mineral density (BMD) in maintenance haemodialysis (MHD) patients with osteoporosis. Methods Twenty-eight MHD patients with osteoporosis diagnosed by dual energy X-ray absorptiometry were randomly divided into control group (n=15) and treatment group (n=13). Patients in treatment group were treated with oral 70 mg alendronate sodium once a week for 18 months. BMD of hip and lumbar spine was measured by dual energy X-ray absorptiometry at baseline and the end of the 6th, 12th and 18th month. Parathyroid hormone, calcium, phosphorous, alkaline phosphatase levels, blood routine, hepatic and renal function were assayed at baseline and the end of the 18th month, Kt/V was calculated, new bone fracture was recorded. Results The BMD, T-scores and Z-scores in the lumbar spine and specific regions of the hip were stable in the treatment group and obviously decreased in the control group (P<0.01). New bone fracture was found in 1 patient of the treatment group and 5 patients of the control group. The side-effect of alendronate sodium was epigastric discomfort in 1 cases. Conclusions Oral alendronate sodium appears to be well tolerated in MHD patients and keep the BMD stable in the lumbar spine and specific regions of the hip.
